US Alcohol Addiction Therapeutics Market Analysis

US Alcohol Addiction Therapeutics Market Executive Summary

The US Alcohol Addiction Therapeutics Market is valued at around $301 Mn in 2022 and is projected to reach $421 Mn by 2030, exhibiting a CAGR of 4.3% during the forecast period.

Alcohol use disorder (AUD), another name for alcohol addiction, is a medical illness characterized by heavy or regular alcohol consumption, even when it interferes with one's life or negatively impacts one's health. There is no one scientific test used to diagnose AUD; instead, it develops gradually. A discussion with a healthcare professional, forms the basis of the diagnosis. Detoxification, behaviour modification, psychotherapy, and medication are available as forms of treatment. Depending on the patient's condition and recovery level, the type of treatment will vary and may include inpatient treatment (hospital), outpatient intensive therapy, residential rehabilitation (rehab), or outpatient maintenance. For the treatment of AUD, there are pharmaceuticals such as acamprosate, naltrexone, and disulfiram, as well as behavioural therapies like cognitive-behavioural therapy (CBT)

Over the age of 12, 1 in 10 Americans suffers from an AUD. 10.5% of those aged 12 and over, or around 29.5 Mn individuals, reported having AUD in the past year. This comprises 12.2 Mn females and 17.4 Mn males aged 12 and older (8.5% and 12.6%, respectively, in this age range). This trend is growing at an accelerated rate since the COVID-19 lockdowns. The market is driven by a mix of factors, such as the increasing prevalence of alcohol addiction in the US, the presence of promising drugs in the pipeline, and increased coverage of therapeutics by insurance providers.

In 2022, Alkermes's primary product, Vivitrol, brought in around $1 Bn in sales worldwide, most of which reportedly came from the US market. Even if they may not individually take the top rank, businesses like GSK and Lundbeck, which have well-known brands like Selinex and Campral, contribute significantly to the US Alcohol Addiction Therapeutics Market

Market Dynamics

Market Drivers

Increasing prevalence: Millions of Americans are impacted by AUD, as one in ten adults and adolescents in the US struggle with it. The yearly economic cost of AUD, including missed productivity and medical expenses, is more than $249 Bn. For the benefit of the whole nation, it is imperative that the growing prevalence be addressed and the problem be resolved. Due to the scarcity of AUD treatment alternatives, there is a growing market need for novel and advanced therapies in the country.

Pipeline Drugs: Prescriptions for long-acting injectable naltrexone, such as VIVITROL, increased by 30% between 2020 and 2022. There are more than 50 new AUD medicines in various stages of research in the pipeline. New and promising solutions for treating AUD have been made possible by technological improvements in pharmaceutical development.

Increasing coverage and reimbursement: In order to improve access and reimbursement, policies are being changed, and this is making the healthcare system more equal for those with AUD. Treatment for mental health and drug addiction must be covered equally with other medical diseases, according to the Mental Health Parity and Addiction Equity Act. Millions of Americans now have more insurance coverage for AUD treatment because to the Affordable Care Act's Medicaid expansion.

Market Restraints

Lack of Knowledge and Acceptance of Addiction: Almost 60% of AUD sufferers do not undergo treatment because of things like a lack of knowledge or acceptance of their illness. Admitting that they have a problem makes people feel horrible. The social stigma associated with addiction might occasionally persist, which deters people from getting treatment. Erroneous beliefs about addiction as a sickness rather than a moral shortcoming exacerbate the issue. This reduces the demand for therapy.

Therapy Cost: Even with insurance coverage, the high out-of-pocket expenses linked to certain treatment alternatives can be a major barrier. Their reach is limited by the cost and insurance coverage of some medications, such as long-acting naltrexone injectables. Furthermore, accessibility and extension of AUD treatment programs are limited by a lack of public financing.

Social problems and Attitude: When heavy drinking becomes accepted in some social settings, it might minimize the seriousness of AUD and hinder treatment. The easy availability to alcohol through a variety of channels, even to minors, raises the risk of alcohol abuse and the emergence of AUD. Additionally, rehabilitation attempts may be hampered by inadequate social support networks for those who are addicted.

Healthcare Policies and Regulatory Landscape

The safety, effectiveness, and accessibility of healthcare services and goods are the main goals of the extensive array of laws and programs that make up US healthcare policies. The US Food and Drug Administration (US FDA), the nation's drug regulatory agency, is mostly responsible for managing the pharmaceutical sector. It is one of the most powerful drug regulatory organizations in the world and is vital to drug regulation not just in the US but in most parts of the world. It is in charge of assessing a medication's efficacy and safety prior to marketing it, as well as overseeing and controlling its usage beyond that point. The FDA plays a critical role in addressing pressing public health issues and providing guidance for the creation and execution of regulatory actions. In order to maintain data integrity in international clinical trials, the agency also works with other international regulatory authorities, highlighting the significance of data quality management procedures and human subject protection.

Competitive Landscape

Key Players

• Alkermes
• TEVA
• GlaxoSmithKline
• Lundbeck
• Eli Lilly
• BioCorRx
• Chronos
• AstraZeneca
• Roche
• Opiant Pharmaceuticals